Companies / Board change
Inhibikase adds Kailera's Scott Wasserman to its board as Dennis Berman steps down
Wasserman, a cardiologist and Kailera Therapeutics' chief medical officer, takes a Class III seat running to the 2029 annual meeting and joins the compensation committee. The 8-K discloses an option grant of up to 310,000 shares.